Pharmacological Evaluation of TAK-828F, a Novel Orally Available RORγt Inverse Agonist, on Murine Colitis Model

[1]  Biching Sang,et al.  Biochemical Properties of TAK-828F, a Potent and Selective Retinoid-Related Orphan Receptor Gamma t Inverse Agonist , 2018, Pharmacology.

[2]  D. Soler,et al.  MLN3126, an antagonist of the chemokine receptor CCR9, ameliorates inflammation in a T cell mediated mouse colitis model , 2018, International immunopharmacology.

[3]  M. Sagara,et al.  Pharmacological inhibitory profile of TAK‐828F, a potent and selective orally available ROR&ggr;t inverse agonist , 2018, Biochemical pharmacology.

[4]  Biching Sang,et al.  Discovery of [ cis-3-({(5 R)-5-[(7-Fluoro-1,1-dimethyl-2,3-dihydro-1 H-inden-5-yl)carbamoyl]-2-methoxy-7,8-dihydro-1,6-naphthyridin-6(5 H)-yl}carbonyl)cyclobutyl]acetic Acid (TAK-828F) as a Potent, Selective, and Orally Available Novel Retinoic Acid Receptor-Related Orphan Receptor γt Inverse Agonis , 2018, Journal of medicinal chemistry.

[5]  A. Kaser,et al.  Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study , 2017, The Lancet.

[6]  D. McAuley,et al.  Innate Lymphoid Cells Are the Predominant Source of IL-17A during the Early Pathogenesis of Acute Respiratory Distress Syndrome. , 2016, American journal of respiratory and critical care medicine.

[7]  J. Kelsen,et al.  Transient inhibition of ROR-γt therapeutically limits intestinal inflammation by reducing TH17 cells and preserving group 3 innate lymphoid cells , 2016, Nature Medicine.

[8]  G. Kaplan,et al.  The global burden of IBD: from 2015 to 2025 , 2015, Nature Reviews Gastroenterology &Hepatology.

[9]  Adam R. Johnson,et al.  Discovery of 1-{4-[3-fluoro-4-((3s,6r)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-ylmethyl)-phenyl]-piperazin-1-yl}-ethanone (GNE-3500): a potent, selective, and orally bioavailable retinoic acid receptor-related orphan receptor C (RORc or RORγ) inverse agonist. , 2015, Journal of medicinal chemistry.

[10]  Zhanju Liu,et al.  Serum Levels of Lipopolysaccharide and 1,3-β-D-Glucan Refer to the Severity in Patients with Crohn's Disease , 2015, Mediators of inflammation.

[11]  T. Schoeb,et al.  Th17 cells give rise to Th1 cells that are required for the pathogenesis of colitis , 2015, Proceedings of the National Academy of Sciences.

[12]  Sung Hee Lee,et al.  Intestinal Permeability Regulation by Tight Junction: Implication on Inflammatory Bowel Diseases , 2015, Intestinal research.

[13]  J. Preiß,et al.  Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease. , 2015, The Cochrane database of systematic reviews.

[14]  M. Seidl,et al.  Comprehensive Intestinal T Helper Cell Profiling Reveals Specific Accumulation of IFN-&ggr;+IL-17+Coproducing CD4+ T Cells in Active Inflammatory Bowel Disease , 2014, Inflammatory bowel diseases.

[15]  Xiuqin Cheng,et al.  Elevated levels of Th17 cells and Th17-related cytokines are associated with disease activity in patients with inflammatory bowel disease , 2014, Inflammation Research.

[16]  Mark S. Sundrud,et al.  Small-molecule RORγt antagonists inhibit T helper 17 cell transcriptional network by divergent mechanisms. , 2014, Immunity.

[17]  J. Gálvez.  Role of Th17 Cells in the Pathogenesis of Human IBD , 2014, ISRN inflammation.

[18]  Mark S. Sundrud,et al.  Pharmacologic Inhibition of RORγt Regulates Th17 Signature Gene Expression and Suppresses Cutaneous Inflammation In Vivo , 2014, The Journal of Immunology.

[19]  H. Tilg,et al.  Targeting T and B Lymphocytes in Inflammatory Bowel Diseases: Lessons from Clinical Trials , 2013, Digestive Diseases.

[20]  A. M’Koma,et al.  Inflammatory Bowel Disease: An Expanding Global Health Problem , 2013, Clinical medicine insights. Gastroenterology.

[21]  D. Littman,et al.  Small molecule inhibitors of RORγt: Targeting Th17 cells and other applications , 2012, European journal of immunology.

[22]  J. Shimizu,et al.  Excessive CD4+ T cells co‐expressing interleukin‐17 and interferon‐γ in patients with Behçet's disease , 2012, Clinical and experimental immunology.

[23]  M. Roncarolo,et al.  The Cellular and Molecular Mechanisms of Immuno-Suppression by Human Type 1 Regulatory T Cells , 2011, Front. Immun..

[24]  H. Ogata,et al.  Regulatory T cells suppress development of colitis, blocking differentiation of T-helper 17 into alternative T-helper 1 cells. , 2011, Gastroenterology.

[25]  S. Hanauer.  The expanding role of biologic therapy for IBD , 2010, Nature Reviews Gastroenterology &Hepatology.

[26]  D. Rampton,et al.  DIFFERENTIAL REGULATION OF INTERLEUKIN-17 AND INTERFERON- PRODUCTION IN INFLAMMATORY BOWEL DISEASE , 2011 .

[27]  P. Duquette,et al.  Preferential recruitment of interferon‐γ–expressing TH17 cells in multiple sclerosis , 2009, Annals of neurology.

[28]  M. Veldhoen,et al.  Interleukin-17-producing gammadelta T cells selectively expand in response to pathogen products and environmental signals. , 2009, Immunity.

[29]  K. Takeda,et al.  TGF-beta is necessary for induction of IL-23R and Th17 differentiation by IL-6 and IL-23. , 2009, Biochemical and biophysical research communications.

[30]  C. Elson,et al.  Late developmental plasticity in the T helper 17 lineage. , 2009, Immunity.

[31]  B. Becher,et al.  RORgamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. , 2009, Gastroenterology.

[32]  W. Paul,et al.  CD4 T cells: fates, functions, and faults. , 2008, Blood.

[33]  H. Weiner,et al.  Control of Treg and TH17 cell differentiation by the aryl hydrocarbon receptor , 2008, Nature.

[34]  A. Rachitskaya,et al.  Cutting Edge: NKT Cells Constitutively Express IL-23 Receptor and RORγt and Rapidly Produce IL-17 upon Receptor Ligation in an IL-6-Independent Fashion1 , 2008, The Journal of Immunology.

[35]  D. Littman,et al.  The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. , 2006, Cell.

[36]  J. Pearson,et al.  The MUC2 gene product: a human intestinal mucin. , 1998, The international journal of biochemistry & cell biology.

[37]  Hervé Groux,et al.  A CD4+T-cell subset inhibits antigen-specific T-cell responses and prevents colitis , 1997, Nature.

[38]  F. Annunziato,et al.  Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease. , 1997, The American journal of pathology.

[39]  M. Neurath,et al.  Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. , 1996, Journal of immunology.